Trial Profile
Pharmacokinetics and Safety of Coadministered Paritaprevir plus Ritonavir (Paritaprevir/r), Ombitasvir, and Dasabuvir in Hepatic Impairment.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Dec 2015
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors AbbVie
- 04 Dec 2015 New trial record